PUBLIC COMPANY

$ATNMActinium Pharmaceuticals, Inc.

New York, NY, USupdated 1mo ago

SEC EDGAR Yahoo Finance

community read0 votes

pipeline

2

marketed

0

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Phase 21Phase 3

Phase 3

iodine i 131 apamistamab

Refractory Acute Myeloid Leukemia

Phase 2

actinium (225Ac) lintuzumab satetraxetan

Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Actinium Pharmaceuticals, Inc. jobs →

News

no news has mentioned this company yet

Data sources

SEC EDGAR

last refreshed 28m ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

$ATNM

Active trials

phase3Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLnot yet recruitingn=306
phase2Venetoclax and Lintuzumab-Ac225 in AML Patientsunknownn=38
phase2Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patientscompletedn=40
phase2Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patientswithdrawn
phase3Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemiaactive not recruitingn=153